Showing: 1 - 10 of 27 RESULTS
Biotech Briefing Psychedelics Revive Therapeutics

Revive Therapeutics Announces Research Collaboration Agreement For Psilocybin Microneedle Patch

Revive Therapeutics (CSE: RVV) announced today that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (CSE: PHRM). The agreement seeks to evaluate delivering psilocybin with the latter’s microneedle patch technology for treating neuropsychiatric disorders. PharmaTher is conducting studies with MicroDose-MN–a biocompatible and biodegradable gelatin methacryloyl microneedle patch to deliver psilocybin. The studies …

Briefing News Psilocybin Psychedelics Revive Therapeutics

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its psychedelic assets. The update primarily focused on the current status of the firms various psychedelics-related development and clinical programs, which largely surround the use of psilocybin. The company currently has a number of ongoing studies as they relate to the …

Briefing News Psychedelics Revive Therapeutics

Revive Therapeutics Partners With University of Health Sciences Antigua To Further Psychedelics Research

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a collaboration to further advance its psychedelic-assisted therapies. The company will be working with the University of Health Sciences Antigua, or UHSA, to pioneer clinical research and development of psychedelics within Antigua and Barbuda. Under the collaboration, the duo intends to develop a …

Briefing News Psilocybin Psychedelics Revive Therapeutics

Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an oral thin film delivery system with psilocybin, as well as filed for a related provisional patent for the technology with the US Patent and Trademark office. The thin film technology with developed under a research partnership with the Reed Research …

Briefing News Psychedelics Revive Therapeutics

Revive Therapeutics Reports Successful Results Using Psilocybin To Treat Traumatic Brain Injury

Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a pre-clinical study that evaluated the efficacy of psilocybin in the treatment of mild traumatic brain injury. The pre-clinical trial was conducted in a rodent model of such an injury. Conducted by the National Health Research Institute, the study focused on …

Briefing News Pharmather Psychedelics Revive Therapeutics

PharmaTher, Revive, Complete Psilocybin Intellectual Property Transaction

PharmaTher (CSE: PHRM) has seen the completion of the sale of its psilocybin program to that of Revive Therapeutics (CSE: RVV). Under the terms of the agreement, Revive has acquired the full rights to PharmaTher’s intellectual property as it pertains to psilocybin. The assets sold under the arrangement includes a number of IP, including all …